PMID- 20668229 OWN - NLM STAT- MEDLINE DCOM- 20101221 LR - 20211203 IS - 1528-0020 (Electronic) IS - 0006-4971 (Linking) VI - 116 IP - 20 DP - 2010 Nov 18 TI - The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. PG - 4262-73 LID - 10.1182/blood-2010-02-269837 [doi] AB - Finding an effective treatment for acute myeloid leukemia (AML) remains a challenge, and all cellular processes that are deregulated in AML cells should be considered in the design of targeted therapies. We show in our current study that the LKB1/AMPK/TSC tumor suppressor axis is functional in AML and can be activated by the biguanide molecule metformin, resulting in a specific inhibition of mammalian target of rapamycin (mTOR) catalytic activity. This induces a multisite dephosphorylation of the key translation regulator, 4E-BP1, which markedly inhibits the initiation step of mRNA translation. Consequently, metformin reduces the recruitment of mRNA molecules encoding oncogenic proteins to the polysomes, resulting in a strong antileukemic activity against primary AML cells while sparing normal hematopoiesis ex vivo and significantly reducing the growth of AML cells in nude mice. The induction of the LKB1/AMPK tumor-suppressor pathway thus represents a promising new strategy for AML therapy. FAU - Green, Alexa S AU - Green AS AD - Institut Cochin, Universite Paris Descartes, CNRS (UMR8104), Paris, France. FAU - Chapuis, Nicolas AU - Chapuis N FAU - Maciel, Thiago Trovati AU - Maciel TT FAU - Willems, Lise AU - Willems L FAU - Lambert, Mireille AU - Lambert M FAU - Arnoult, Christophe AU - Arnoult C FAU - Boyer, Olivier AU - Boyer O FAU - Bardet, Valerie AU - Bardet V FAU - Park, Sophie AU - Park S FAU - Foretz, Marc AU - Foretz M FAU - Viollet, Benoit AU - Viollet B FAU - Ifrah, Norbert AU - Ifrah N FAU - Dreyfus, Francois AU - Dreyfus F FAU - Hermine, Olivier AU - Hermine O FAU - Moura, Ivan Cruz AU - Moura IC FAU - Lacombe, Catherine AU - Lacombe C FAU - Mayeux, Patrick AU - Mayeux P FAU - Bouscary, Didier AU - Bouscary D FAU - Tamburini, Jerome AU - Tamburini J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100728 PL - United States TA - Blood JT - Blood JID - 7603509 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Cell Cycle Proteins) RN - 0 (EIF4EBP1 protein, human) RN - 0 (Neoplasm Proteins) RN - 0 (Phosphoproteins) RN - 0 (Tuberous Sclerosis Complex 2 Protein) RN - 0 (Tumor Suppressor Proteins) RN - 9100L32L2N (Metformin) RN - EC 2.7.- (Protein Kinases) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.11.1 (STK11 protein, human) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases) SB - IM MH - AMP-Activated Protein Kinase Kinases MH - Adaptor Proteins, Signal Transducing/metabolism MH - Animals MH - Biocatalysis/drug effects MH - Cell Cycle Proteins MH - Cell Death/drug effects MH - Cell Proliferation/drug effects MH - Enzyme Activation/drug effects MH - Hematopoietic Stem Cells/cytology/drug effects/metabolism MH - Humans MH - Leukemia, Myeloid, Acute/*enzymology/genetics/pathology MH - Metformin/pharmacology MH - Mice MH - Neoplasm Proteins/*biosynthesis MH - Phosphoproteins/metabolism MH - Phosphorylation/drug effects MH - Polyribosomes/drug effects/metabolism MH - *Protein Biosynthesis/drug effects MH - Protein Kinases/*metabolism MH - Protein Serine-Threonine Kinases/*metabolism MH - *Signal Transduction/drug effects MH - TOR Serine-Threonine Kinases/*metabolism MH - Tuberous Sclerosis Complex 2 Protein MH - Tumor Suppressor Proteins/metabolism EDAT- 2010/07/30 06:00 MHDA- 2010/12/22 06:00 CRDT- 2010/07/30 06:00 PHST- 2010/07/30 06:00 [entrez] PHST- 2010/07/30 06:00 [pubmed] PHST- 2010/12/22 06:00 [medline] AID - S0006-4971(20)31066-1 [pii] AID - 10.1182/blood-2010-02-269837 [doi] PST - ppublish SO - Blood. 2010 Nov 18;116(20):4262-73. doi: 10.1182/blood-2010-02-269837. Epub 2010 Jul 28.